JIANGSU HENGRUI MEDICINE CO., LTD.

Press Releases Jiangsu Hengrui Medicine Co., Ltd.

Equities

600276

CNE0000014W7

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
45.61 ^CNY	+2.96%		+9.43%	+0.84%

Apr. 26	Hengrui Pharma Gets Nod to Trial Insulin Aspart Injection; Shares Up 3%	MT
Apr. 17	Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd's Commercial Launch of VIVJOA Capsules for the Treatment of Severe Vulvovaginal Candidiasis in China	Feb. 08	AQ
Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 \| Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.	Dec. 05	AQ
HER2-mutant Non-Small Cell Lung Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	Nov. 22	AQ
Autoimmune Hepatitis Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	Nov. 09	AQ
Acute Pain Pipeline, Clinical and Non-Clinical Stages Products, and FDA Approvals 2023 (Updated)	23-09-27	AQ
Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd's Approval of Oteseconazole Capsules for the Treatment of Severe Vulvovaginal Candidiasis in China	23-08-22	AQ
Jiangsu Hengrui Medicine : Hengrui Pharma Announces Positive Data of Two ADC Programs at the AACR Annual Meeting 2023	23-04-10	PU
Advanced Gastric Carcinoma Pipeline Assessment of Active Pipeline Assets Segmented by Stage, Product Type, Route of Administration, and Molecule Type	23-03-14	AQ
Thermo Fisher Scientific : Signs Companion Diagnostic Agreement with Hengrui Therapeutics Inc	20-08-18	AQ
Jiangsu Hengrui Medicine : Mycovia Pharmaceuticals and Jiangsu Hengrui Medicine Announce Partnership to Develop and Commercialize VT-1161 for Recurrent Vulvovaginal Candidiasis and Other Fungal Conditions	19-06-17	BU
Jiangsu Hengrui Medicine : and Arcutis Announce a Development and Commercialization Partnership for Novel Immune-Mediated Dermatology Therapy Using SHR0302	18-01-05	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer